Compare PPG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPG | INSM |
|---|---|---|
| Founded | 1883 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paints/Coatings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6B | 22.4B |
| IPO Year | 2014 | 2000 |
| Metric | PPG | INSM |
|---|---|---|
| Price | $106.18 | $115.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | $124.25 | ★ $201.17 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 46.11 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.42 | $182.31 |
| Revenue Next Year | $3.03 | $65.19 |
| P/E Ratio | $62.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $93.39 | $90.39 |
| 52 Week High | $133.43 | $212.75 |
| Indicator | PPG | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 41.42 |
| Support Level | $103.71 | $97.66 |
| Resistance Level | $107.99 | $119.54 |
| Average True Range (ATR) | 2.01 | 4.76 |
| MACD | 0.34 | -1.10 |
| Stochastic Oscillator | 57.81 | 8.29 |
PPG is the world's second-largest producer of paints and coatings. PPG's products are sold to a wide variety of end users, including industrial segments such as automotive, aerospace, and protective and marine, as well as paint contractors and do-it-yourself customers. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.